Dr Jane Meisel comments on the findings from a phase 3 randomised study, known as DESTINY-Breast04, investigating trastuzumab deruxtecan versus treatment of physician’s choice in patients (pts) with HER2-low unresectable and or metastatic breast cancer.

The primary outcome was that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.

Dr Meisel concludes the by discussing the significance of the study findings.

Watch Dr Modi's press conference on the study here

Watch Dr Modi's interview on the study here

Read the news story here